Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava.

There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation. 

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial both tor the “forgotten” valve alone or in combination with the mitral valve. 

The study looked at 122 patients from the TriValve registry receiving combined transcatheter mitral plus tricuspid valve edge-to-edge repair (TMTVR) and 106 from the TRAMI registry receiving transcatheter mitral valve edge-to-edge repair (TMVR). They also presented severe tricuspid regurgitation. 

Mean age was 77; those receiving TMTVR were mostly women, had less severe left ventricular function deterioration <30% (18% vs. 39.4% p<0.001), end-diastole diameter (54 mm vs. 59 mm; p = 0.007), atrial fibrillation (68.7% vs. 55.7%; p= 0.029) and cardiac failure functional class IV (32.8% vs. 18.9%; p=0.013). In addition, glomerular filtration was lower.


Read also: Impella and Adverse Events.


EuroSCORE in the TRAMI group was 26.2% and in the TriValve group was 12.1%. Tricuspid annulus dilation was 47±8 mm in the TriValve group.

Procedural success in the mitral valve was similar, and was 81% in the tricuspid. In patients undergoing TMTVR, procedure duration prolonged 50 minutes. There were no differences in hospital evolution.


Read also: ACC Recommendations against the New Coronavirus.


At one-year follow-up, mortality was higher in TMVR patients (34% vs. 16.1% p=0.035), with no differences functional class improvement, which was significant. 

Conclusion

Joint treatment of both valves was associated to better survival vs. isolated mitral valve treatment in patients with severe mitral and tricuspid regurgitation. More randomized studies are necessary to confirm these results. 

Courtesy of Dr. Carlos Fava.

Original title: Combined Tricuspid and Mitral VersusIsolated Mitral Valve Repair for Severe Mitral and Tricuspid Regurgitation An Analysis From the TriValve and TRAMI Registries.

Reference: Michael Mehr, et al J Am Coll cardiol Intev 2020;13:543-50.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...